TransMedics Group/$TMDX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About TransMedics Group
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Ticker
$TMDX
Sector
Primary listing
Employees
728
Headquarters
Website
TMDX Metrics
BasicAdvanced
$4.3B
49.08
$2.54
2.05
-
Price and volume
Market cap
$4.3B
Beta
2.05
52-week high
$145.50
52-week low
$55.00
Average daily volume
982K
Financial strength
Current ratio
7.689
Quick ratio
6.86
Long term debt to equity
143.894
Total debt to equity
146.213
Interest coverage (TTM)
6.85%
Profitability
EBITDA (TTM)
120.551
Gross margin (TTM)
60.28%
Net profit margin (TTM)
16.20%
Operating margin (TTM)
16.94%
Effective tax rate (TTM)
1.20%
Revenue per employee (TTM)
$780,000
Management effectiveness
Return on assets (TTM)
6.93%
Return on equity (TTM)
32.48%
Valuation
Price to earnings (TTM)
49.077
Price to revenue (TTM)
7.436
Price to book
11.96
Price to tangible book (TTM)
12.44
Price to free cash flow (TTM)
34.906
Free cash flow yield (TTM)
2.86%
Free cash flow per share (TTM)
3.566
Growth
Revenue change (TTM)
41.20%
Earnings per share change (TTM)
170.70%
3-year revenue growth (CAGR)
99.11%
3-year earnings per share growth (CAGR)
19.65%
What the Analysts think about TMDX
Analyst ratings (Buy, Hold, Sell) for TransMedics Group stock.
Bulls say / Bears say
Total revenue for the second quarter of 2025 reached $157.4 million, up 38% year-over-year, leading management to raise full-year guidance to $585 million–$605 million (PRNewswire).
TransMedics posted net income of $34.9 million, or $0.92 per fully diluted share, in Q2 2025, showing strong improvement in bottom-line profitability (PRNewswire).
The company received conditional IDE approval from the U.S. FDA to begin the Next-Gen OCS™ Lung trial, and launched the NOP ACCESS™ digital ecosystem, strengthening its product pipeline and service offerings (PRNewswire).
Quarterly revenue growth slowed from 48% in Q1 to 38% in Q2 2025, raising concerns about whether the company can maintain its pace of rapid expansion (Investor's Business Daily).
TransMedics trades at a trailing P/E ratio of 96, which is much higher than peers such as CONMED Corp. at 19.36, suggesting its valuation may be stretched compared to the industry average (MarketsMojo).
The company is facing a class-action lawsuit alleging fraudulent practices and safety violations, which exposes it to potential legal and reputational risks (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2025.
TMDX Financial Performance
Revenues and expenses
TMDX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for TransMedics Group stock?
TransMedics Group (TMDX) has a market cap of $4.3B as of November 06, 2025.
What is the P/E ratio for TransMedics Group stock?
The price to earnings (P/E) ratio for TransMedics Group (TMDX) stock is 49.08 as of November 06, 2025.
Does TransMedics Group stock pay dividends?
No, TransMedics Group (TMDX) stock does not pay dividends to its shareholders as of November 06, 2025.
When is the next TransMedics Group dividend payment date?
TransMedics Group (TMDX) stock does not pay dividends to its shareholders.
What is the beta indicator for TransMedics Group?
TransMedics Group (TMDX) has a beta rating of 2.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.